CD274 and gastroesophageal junction adenocarcinoma: In the GEMSTONE-303 trial, compared with PLA-CAP, SUG-CAP as a first-line treatment showed clinical efficacy for advanced G/GEJ adenocarcinoma with PD-L1 CPS ≥5, extending the median OS by 3 months and median PFS by 1.5 months and exhibiting good tolerability.